OBJECTIVE: To investigate the effects of rituximab on retinal atrophy in patients with relapsing-remitting multiple sclerosis (RRMS), we performed serial optical coherence tomography (OCT) scans among a cohort of patients with RRMS on rituximab and compared rates of ganglion cell + inner plexiform layer (GCIPL) atrophy to those observed among age- and sex-matched glatiramer acetate (GA)-and natalizumab-treated patients with RRMS and healthy controls (HCs). METHODS: In this observational study, patients with RRMS treated with a single disease-modifying therapy and HCs were followed with serial OCT for a median duration of 2.8 years. Participants with uncontrolled hypertension, diabetes mellitus, or glaucoma, and eyes with optic neuritis ≤6 months prior to baseline OCT, or during follow-up, were excluded. Statistical analyses were performed using linear mixed-effects regression. RESULTS: During the overall follow-up period, rates of GCIPL atrophy were -0.28 ± 0.11 µm/y among rituximab-treated patients with RRMS (n = 35). This was similar to GA-treated (n = 49; -0.33 ± 0.05 µm/y; p = 0.69) and natalizumab-treated patients (n = 88; -0.17 ± 0.10 µm/y; p = 0.13) and faster than HCs (n = 78; -0.15 ± 0.03 µm/y; p = 0.006). Rituximab-treated patients exhibited 0.55 ± 0.23 µm/y faster rates of GCIPL atrophy during the first 12 months of treatment, relative to afterwards (n = 25; p = 0.02), during which period GCIPL atrophy rates were -0.14 ± 0.13 µm/y. CONCLUSIONS: Retinal atrophy in RRMS is modulated by rituximab. Greater attenuation of retinal atrophy may occur after 12 months of rituximab treatment, following which time GCIPL atrophy rates are similar to those observed among natalizumab-treated patients with RRMS and HCs. Our findings raise the possibility that the neuroprotective therapeutic response with rituximab in RRMS may take up to 12 months, which should be confirmed by larger studies. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence on the difference in rate of change of the GCIPL thickness in patients with RRMS comparing rituximab to other disease-modifying therapies.
OBJECTIVE: To investigate the effects of rituximab on retinal atrophy in patients with relapsing-remitting multiple sclerosis (RRMS), we performed serial optical coherence tomography (OCT) scans among a cohort of patients with RRMS on rituximab and compared rates of ganglion cell + inner plexiform layer (GCIPL) atrophy to those observed among age- and sex-matched glatiramer acetate (GA)-and natalizumab-treated patients with RRMS and healthy controls (HCs). METHODS: In this observational study, patients with RRMS treated with a single disease-modifying therapy and HCs were followed with serial OCT for a median duration of 2.8 years. Participants with uncontrolled hypertension, diabetes mellitus, or glaucoma, and eyes with optic neuritis ≤6 months prior to baseline OCT, or during follow-up, were excluded. Statistical analyses were performed using linear mixed-effects regression. RESULTS: During the overall follow-up period, rates of GCIPL atrophy were -0.28 ± 0.11 µm/y among rituximab-treated patients with RRMS (n = 35). This was similar to GA-treated (n = 49; -0.33 ± 0.05 µm/y; p = 0.69) and natalizumab-treated patients (n = 88; -0.17 ± 0.10 µm/y; p = 0.13) and faster than HCs (n = 78; -0.15 ± 0.03 µm/y; p = 0.006). Rituximab-treated patients exhibited 0.55 ± 0.23 µm/y faster rates of GCIPL atrophy during the first 12 months of treatment, relative to afterwards (n = 25; p = 0.02), during which period GCIPL atrophy rates were -0.14 ± 0.13 µm/y. CONCLUSIONS: Retinal atrophy in RRMS is modulated by rituximab. Greater attenuation of retinal atrophy may occur after 12 months of rituximab treatment, following which time GCIPL atrophy rates are similar to those observed among natalizumab-treated patients with RRMS and HCs. Our findings raise the possibility that the neuroprotective therapeutic response with rituximab in RRMS may take up to 12 months, which should be confirmed by larger studies. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence on the difference in rate of change of the GCIPL thickness in patients with RRMS comparing rituximab to other disease-modifying therapies.
Authors: R T Naismith; L Piccio; J A Lyons; J Lauber; N T Tutlam; B J Parks; K Trinkaus; S K Song; A H Cross Journal: Neurology Date: 2010-06-08 Impact factor: 9.910
Authors: Julia Button; Omar Al-Louzi; Andrew Lang; Pavan Bhargava; Scott D Newsome; Teresa Frohman; Laura J Balcer; Elliot M Frohman; Jerry Prince; Peter A Calabresi; Shiv Saidha Journal: Neurology Date: 2017-01-11 Impact factor: 9.910
Authors: Shiv Saidha; Stephanie B Syc; Mary K Durbin; Christopher Eckstein; Jonathan D Oakley; Scott A Meyer; Amy Conger; Teresa C Frohman; Scott Newsome; John N Ratchford; Elliot M Frohman; Peter A Calabresi Journal: Mult Scler Date: 2011-08-24 Impact factor: 6.312
Authors: Axel Petzold; Laura J Balcer; Peter A Calabresi; Fiona Costello; Teresa C Frohman; Elliot M Frohman; Elena H Martinez-Lapiscina; Ari J Green; Randy Kardon; Olivier Outteryck; Friedemann Paul; Sven Schippling; Patrik Vermersch; Pablo Villoslada; Lisanne J Balk Journal: Lancet Neurol Date: 2017-09-12 Impact factor: 44.182
Authors: Angeliki G Filippatou; Jeffrey Lambe; Elias S Sotirchos; Kathryn C Fitzgerald; Andrew Aston; Olwen C Murphy; Nicole Pellegrini; Nicholas Fioravante; Hunter Risher; Esther Ogbuokiri; Ohemaa Kwakyi; Brandon Toliver; Simidele Davis; Nicholas Luciano; Ciprian Crainiceanu; Jerry L Prince; Ellen M Mowry; Peter A Calabresi; Shiv Saidha Journal: Mult Scler Date: 2020-04-16 Impact factor: 6.312
Authors: S Schippling; L J Balk; F Costello; P Albrecht; L Balcer; P A Calabresi; J L Frederiksen; E Frohman; A J Green; A Klistorner; O Outteryck; F Paul; G T Plant; G Traber; P Vermersch; P Villoslada; S Wolf; A Petzold Journal: Mult Scler Date: 2014-06-16 Impact factor: 6.312
Authors: Ludwig Kappos; Paul W O'Connor; Christopher H Polman; Patrick Vermersch; Heinz Wiendl; Amy Pace; Annie Zhang; Christophe Hotermans Journal: J Neurol Date: 2013-01-05 Impact factor: 4.849
Authors: Prejaas Tewarie; Lisanne Balk; Fiona Costello; Ari Green; Roland Martin; Sven Schippling; Axel Petzold Journal: PLoS One Date: 2012-04-19 Impact factor: 3.240
Authors: Andrew Lang; Aaron Carass; Matthew Hauser; Elias S Sotirchos; Peter A Calabresi; Howard S Ying; Jerry L Prince Journal: Biomed Opt Express Date: 2013-06-14 Impact factor: 3.732
Authors: David H Miller; Omar A Khan; William A Sheremata; Lance D Blumhardt; George P A Rice; Michele A Libonati; Allison J Willmer-Hulme; Catherine M Dalton; Katherine A Miszkiel; Paul W O'Connor Journal: N Engl J Med Date: 2003-01-02 Impact factor: 91.245
Authors: Christian Cordano; Bardia Nourbakhsh; Hao H Yiu; Nico Papinutto; Eduardo Caverzasi; Ahmed Abdelhak; Frederike C Oertel; Alexandra Beaudry-Richard; Adam Santaniello; Simone Sacco; Daniel J Bennett; Apraham Gomez; Christina J Sigurdson; Stephen L Hauser; Roberta Magliozzi; Bruce A C Cree; Roland G Henry; Ari J Green Journal: Neurology Date: 2022-08-29 Impact factor: 11.800